Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

NCT02667223 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early on July 8, 2016 due to business priorities regarding study execution.

Conditions

Healthy
Hypercholesterolemia

Interventions

BIOLOGICAL: Cohort 1: bococizumab 150 mg + rHuPH20
BIOLOGICAL: Cohort 2: bococizumab 300 mg
BIOLOGICAL: Cohort 3: bococizumab 300 mg + rHuPH20
BIOLOGICAL: Cohort 5: bococizumab 450 mg + rHuPH20
BIOLOGICAL: Cohort 4: bococizumab 300 mg + rHuPH20

Sponsor

Pfizer

Collaborators

[object Object]